Akeso, Inc. (HK:9926) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Akeso, Inc. has announced the approval of its non-oncology drug, ebronucimab (PCSK9), by China’s National Medical Products Administration for treating hypercholesterolemia and familial hypercholesterolaemia. This marks the company’s fifth commercial product and is expected to meet the high market demand for metabolic disease treatments in China, potentially reducing cardiovascular event risks. The company is optimistic about ebronucimab’s role in strengthening its long-term global development through a targeted commercialization strategy.
For further insights into HK:9926 stock, check out TipRanks’ Stock Analysis page.